Response by Liang and Shimada to Letter Regarding Article “Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy”
Circulation: Heart Failure, Ahead of Print. Source link
Read moreContinuing Education
Letter by Luo and Bu Regarding Article, “Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy”
Circulation: Heart Failure, Ahead of Print. Source link
Read more
Biopsy-Proven Giant Cell Myocarditis Following the COVID-19 Vaccine
Circulation: Heart Failure, <a href=”https://www.ahajournals.org/toc/circheartfailure/15/4″>Volume 15, Issue 4</a>, Page e009321, April 1, 2022. Source link
Read moreCorrection to: “Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure”
In the article by Lanfear et al, “Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection
Read moreCorrection to: Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial
In the article by Lai et al, “Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential
Read moreManagement of Hypertension in Patients With Ventricular Assist Devices: A Scientific Statement From the American Heart Association
Abstract Mechanical circulatory support with durable continuous-flow ventricular assist devices has become an important therapeutic management strategy for patients with
Read moreCompounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:Mendelian randomization studies use genetic variants as natural experiments to provide evidence
Read moreMitochondrial Sirtuin-3 (SIRT3) Prevents Doxorubicin-Induced Dilated Cardiomyopathy by Modulating Protein Acetylation and Oxidative Stress
Circulation: Heart Failure, Ahead of Print. BACKGROUND:High doses of doxorubicin put cancer patients at risk for developing dilated cardiomyopathy. Previously,
Read moreRelationship Between Social Vulnerability Indicators and Trial Participant Attrition: Findings From the HYVALUE Trial
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:Social vulnerability indicators are associated with health care inequities and may similarly
Read moreEquitable Representation in Clinical Trials: Looking Beyond Table 1
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Source link
Read more